Xalkori

(crizotinib)
Xalkori 200 MG Oral CapsuleXalkori 250 MG Oral Capsule
NO BOXED WARNING

Dosage & administration

drug label

Xalkori prescribing information

samples

Request Xalkori samples

Online Sample Form
Learn More

prior authorization

Xalkori prior authorization resources

Most recent Xalkori prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeals
Formulary Exception Letter
PA Checklist
Appeals Checklist
Learn More

Benefits investigation

Pfizer Oncology Together Form
Pfizer Oncology Together Form - Spanish
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

pharmacy

Xalkori preferred pharmacy

Pharmacy List

financial assistance

Xalkori financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
HCP Office: Attest & Print Co-Pay Card
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Pfizer Oncology Together Form
Pfizer Oncology Together Form - Spanish
Pfizer Patient Assistance Program
Pfizer Pledge Physician Attestation Form
Learn More

PubMed™ | Xalkori

Xalkori PubMed™ News

patient education

Xalkori patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Pfizer Oncology Patient Access Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Pfizer Oncology Patient Access Guide - Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Xalkori
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Xalkori
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
The ALK and ROS1 Genes
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Financial Assistance Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Caregiver Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Xalkori FAQs

Can XALKORI be used during pregnancy?XALKORI can cause fetal harm when administered to a pregnant woman based on findings from animal studies and its mechanism of action. There are no available data on the use of XALKORI during pregnancy. In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those expected with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity. Therefore, pregnant women should be advised of the potential risk to fetus and XALKORI should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
What is the estimated background risk of birth defects and miscarriage in the U.S. general population?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Is it safe to breastfeed while using XALKORI?There is no information regarding the presence of crizotinib or its metabolites in human milk, or the effects on the breastfed child or on milk production. Because of the potential for adverse reactions in breastfed children, women should not breastfeed during treatment with XALKORI and for 45 days after the final dose.
Should pregnancy testing be performed before starting treatment with XALKORI?Yes, pregnancy testing should be performed prior to initiating XALKORI in females of reproductive potential.
What should females of reproductive potential do during treatment with XALKORI?Females of reproductive potential should use effective contraception during treatment with XALKORI and for at least 45 days after the final dose because XALKORI can cause fetal harm when administered to a pregnant woman.
What should males with female partners of reproductive potential do during treatment with XALKORI?Males with female partners of reproductive potential should use condoms during treatment with XALKORI and for at least 90 days after the final dose because of the potential for genotoxicity.
Can XALKORI be used in pediatric patients?The safety and effectiveness of XALKORI have been established in pediatric patients 1 year of age and older with relapsed or refractory, systemic ALK-positive ALCL or with unresectable, recurrent, or refractory ALK-positive IMT. However, the safety and effectiveness have not been established in pediatric patients younger than 1 year.
What percentage of patients with ALK-positive metastatic NSCLC in clinical studies of XALKORI were 65 years or older?16% of the total number of patients with ALK-positive metastatic NSCLC in clinical studies of XALKORI were 65 years or older.
What percentage of patients with ALK-positive metastatic NSCLC in clinical studies of XALKORI were 75 years or older?3.8% of the total number of patients with ALK-positive metastatic NSCLC in clinical studies of XALKORI were 75 years or older.
Were there any overall differences in safety or effectiveness observed between older patients and younger patients in clinical studies of XALKORI for ALK-positive metastatic NSCLC?No overall differences in safety or effectiveness were observed between older patients and younger patients in clinical studies of XALKORI for ALK-positive metastatic NSCLC.
Were there sufficient numbers of patients age 65 years and older in clinical studies of XALKORI for ROS1-positive metastatic NSCLC to determine if they respond differently from younger patients?No, clinical studies of XALKORI in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patients.
What happens to crizotinib concentrations in patients with pre-existing moderate or severe hepatic impairment?Crizotinib concentrations increase in patients with pre-existing moderate or severe hepatic impairment.
How should XALKORI dosage be adjusted in patients with moderate or severe hepatic impairment?XALKORI dosage should be reduced in patients with moderate or severe hepatic impairment.
Is a dose adjustment recommended in patients with pre-existing mild hepatic impairment?No, a dose adjustment is not recommended in patients with pre-existing mild hepatic impairment.
What happens to crizotinib exposure in patients with pre-existing severe renal impairment?Increased exposure to crizotinib occurs in patients with pre-existing severe renal impairment.
FAQ Data Source